ALACT.PA
Acticor Biotech SAS [ALACT.PA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ALACT.PA Stock Summary
In the News
ALACT.PA Financial details
Company Rating
-
Market Cap
57.19M
Income
-18.66M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
29
Optionable
No
Shortable
Yes
Earnings
30 Apr 2024
P/E
-1.95
Forward P/E
-
PEG
-0.4
P/S
-
P/B
-14.43
P/C
-
P/FCF
-3.24
Quick Ratio
0.98
Current Ratio
1.75
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.53
EPS next Y
-
EPS next Q
-
EPS this Y
-7.06%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
22.62%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
97.73%
-
-
-
-
SMA20
-10.71%
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-129%
ROE
-379%
ROC
-2.42%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.72-6.26
52W High
-95.83%
52W Low
-87.5%
RSI
33.98
Rel Volume
-
Avg Volume
22.19K
Volume
Perf Week
0%
Perf Month
-26.69%
Perf Quarter
-
Perf Half Y
-41.86%
-
-
-
-
Beta
-0.382
-
-
Volatility
0%, 0.02%
Prev Close
0%
Price
0.25
Change
0%
Company Profile
- Volume Average 22.19K
- Market Capitalization 57.19M
- Employee 29
- CEO Dr. Gilles Avenard M.D.
- Headquarters Paris,FR
- IPO Date 2021-11-01
-
Website
https://acticor-biotech.com 
Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
